文献速递肝病

同种异体粪菌移植改善非酒精性脂肪性肝病患者异常的小肠通透性:一项随机对照试验

Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该随机对照试验将21例非酒精性脂肪性肝病(NAFLD)患者按3:1随机分配至同种异体粪菌移植(FMT)组(n=15)或自体FMT组(n=6),经内镜将粪菌送至远端十二指肠。结果显示两组HOMA-IR和肝脏质子密度脂肪分数(PDFF)均无显著变化,但基线小肠通透性升高(乳果糖/甘露醇>0.025,n=7)的同种异体FMT患者在小肠通透性方面于6周后出现显著降低。

要点

  • 同种异体FMT未改善NAFLD患者的HOMA-IR或肝脏PDFF。
  • 基线小肠通透性升高(乳果糖/甘露醇>0.025)的同种异体FMT患者6周后小肠通透性显著降低。
  • FMT可能具有降低NAFLD患者小肠通透性的潜力。

核心结论

  • FMT未改善以HOMA-IR衡量的胰岛素抵抗或肝脏PDFF,但可能降低NAFLD患者的小肠通透性。

研究设计与样本

  • 随机对照试验,招募21例NAFLD患者,按3:1随机分配至同种异体FMT组(n=15)或自体FMT组(n=6),经内镜将粪菌递送至远端十二指肠。
  • 患者访视时间点为基线、FMT后2周、6周和6个月。

主要发现

  • 同种异体FMT组和自体FMT组的HOMA-IR或肝脏PDFF均无显著变化。
  • 基线小肠通透性升高(乳果糖/甘露醇>0.025,n=7)的同种异体FMT患者,在同种异体FMT后6周小肠通透性显著降低。

关键数值与推荐

  • 小肠通透性采用乳果糖/甘露醇尿液试验检测,基线升高定义为乳果糖/甘露醇>0.025。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is an obesity-related disorder that is rapidly increasing in incidence and is considered the hepatic manifestation of the metabolic syndrome. The gut microbiome plays a role in metabolism and maintaining gut barrier integrity. Studies have found differences in the microbiota between NAFLD and healthy patients and increased intestinal permeability in patients with NAFLD. Fecal microbiota transplantation (FMT) can be used to alter the gut microbiome. It was hypothesized that an FMT from a thin and healthy donor given to patients with NAFLD would improve insulin resistance (IR), hepatic proton density fat fraction (PDFF), and intestinal permeability. METHODS: Twenty-one patients with NAFLD were recruited and randomized in a ratio of 3:1 to either an allogenic (n = 15) or an autologous (n = 6) FMT delivered by using an endoscope to the distal duodenum. IR was calculated by HOMA-IR, hepatic PDFF was measured by MRI, and intestinal permeability was tested using the lactulose:mannitol urine test. Additional markers of metabolic syndrome and the gut microbiota were examined. Patient visits occurred at baseline, 2, 6 weeks, and 6 months post-FMT. RESULTS: There were no significant changes in HOMA-IR or hepatic PDFF in patients who received the allogenic or autologous FMT. Allogenic FMT patients with elevated small intestinal permeability (>0.025 lactulose:mannitol, n = 7) at baseline had a significant reduction 6 weeks after allogenic FMT. DISCUSSION: FMT did not improve IR as measured by HOMA-IR or hepatic PDFF but did have the potential to reduce small intestinal permeability in patients with NAFLD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Craven L, Rahman A, Nair Parvathy S, et al. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol. 2020. PMID: 32618656. doi:10.14309/ajg.0000000000000661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。